Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

483 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
Suminokura J, Miyamoto M, Yoshikawa T, Kouta H, Kikuchi Y, Hada T, Ishibashi H, Ito T, Iwahashi H, Kakimoto S, Suzuki R, Matsuura H, Kishimoto N, Takano M. Suminokura J, et al. Among authors: iwahashi h. BMC Cancer. 2022 Feb 16;22(1):176. doi: 10.1186/s12885-022-09271-3. BMC Cancer. 2022. PMID: 35172766 Free PMC article.
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
Soyama H, Miyamoto M, Matsuura H, Iwahashi H, Kakimoto S, Ishibashi H, Sakamoto T, Hada T, Suminokura J, Takano M. Soyama H, et al. Among authors: iwahashi h. Cancer Chemother Pharmacol. 2020 May;85(5):941-947. doi: 10.1007/s00280-020-04070-8. Epub 2020 Apr 11. Cancer Chemother Pharmacol. 2020. PMID: 32279102
Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?
Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Soyama H, Kato K, Ishibashi H, Iwahashi H, Nakatsuka M, Yajima I, Shimizu Y, Aizawa Y, Suguchi Y, Moriiwa M, Goto T, Sasa H, Nagaoka I, Tsuda H, Furuya K. Aoyama T, et al. Among authors: iwahashi h. Cancer Chemother Pharmacol. 2017 Jul;80(1):65-69. doi: 10.1007/s00280-017-3332-7. Epub 2017 May 10. Cancer Chemother Pharmacol. 2017. PMID: 28493032
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H, Miyamoto M, Takano M, Aoyama T, Matsuura H, Sakamoto T, Takasaki K, Kuwahara M, Kato K, Yoshikawa T, Iwahashi H, Tsuda H, Furuya K. Soyama H, et al. Among authors: iwahashi h. Med Oncol. 2017 Nov 22;34(12):201. doi: 10.1007/s12032-017-1058-3. Med Oncol. 2017. PMID: 29168038
483 results